Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

News Network

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Subscribe

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

Panelists discuss how recent advancements in diagnostic strategies and emerging combination therapies are shaping the management of metastatic castration-sensitive prostate cancer to better address patient needs and improve outcomes.

Exploring Treatments for Metastatic Castration-Sensitive Prostate Cancer

Panelists discuss how emerging PD-1 and PD-L1 inhibitors could transform the treatment landscape for non–muscle-invasive bladder cancer, highlighting the importance of a multidisciplinary approach and ongoing clinical trials for high-risk patients.

Advancements and Insights in Non–Muscle-Invasive Bladder Cancer: Emerging PD-1/PD-L1 Inhibitors  

Dr Lowentritt introduces an upcoming series revolving around biomarker utilization in prostate cancer treatment.

Evolving Role of Biomarkers in Prostate Cancer

A panel of bladder cancer specialists review clinical trial data and discuss the evolving therapeutic landscape for BCG-unresponsive non–muscle invasive bladder cancer.

Emerging Treatments for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

A panel of experts discuss recent updates on the use of MRI/ultrasound fusion-guided biopsy in patients with prostate cancer.

The Role of Fusion-Guided Biopsy in the Management of Prostate Cancer

A panel of experts on prostate cancer discuss the role for PSMA-PET imaging, highlighting clinical practices, recent advances, and key updates.

Advances in Imaging for Prostate Cancer: The Role for PSMA-PET Imaging

Following ESMO 2023, a panel of experts on bladder cancer review recent updates and discuss the evolving treatment landscape, with a focus on non–muscle invasive bladder cancer.

ESMO 2023: Immunotherapy Advancements in Bladder Cancer

Michael J. Kennelly, MD, FPMRS, FACS, joined by Kevin D. Benson, MD, MS and Karyn S. Eilber, MD, leads a comprehensive Urology Times® Viewpoints discussion on patient-centric management of overactive bladder (OAB). They cover an overview of OAB, standard care treatments, device and procedural advancements, and practical considerations for patient-centric care. The session delves into diagnostic assessments, symptom presentations, impact on quality of life, guideline recommendations for treatment, and the clinical benefits and limitations of standard pharmacological treatments. The experts also discuss the role of device-based therapies like sacral neuromodulation and intravesical botulinum toxin type A, focusing on patient eligibility, clinical experiences, and managing post-procedure care. They share insights on adapting procedures to enhance patient comfort, managing expectations, and the importance of follow-up care, providing valuable advice for enhancing patient experiences in OAB management.

Patient-centric Care Approach in the Management of Overactive Bladder (OAB)

This Urology Times® Viewpoints video series provides a detailed exploration of non-muscle invasive bladder cancer (NMIBC), led by Dr. Sam Chang of Vanderbilt University and featuring expert panelists Dr. Gary Steinberg, Dr. Sandip Prasad, Dr. Mark Tyson, and Dr. Roger Lee filmed at Society for Urological Oncology (SUO) 2023. The series delves into the nuances of staging and grading NMIBC, emphasizing the differences between low-grade and high-grade tumors and their implications for treatment strategies. The discussion spans a range of topics including the management of high-risk and intermediate-risk NMIBC, the challenges in treating the BCG unresponsive population, and the examination of new therapeutic advances and clinical trials, such as N803, TAR 200, and Cretostimogene Grenadenorepvec, underscoring the importance of personalized care in NMIBC treatment.

Emerging Therapeutic Approaches in High- and Intermediate- Risk NMIBC

A panel of urologists and radiation oncologists who specialize in treating patients with prostate cancer provide comprehensive insights on the utilization of rectal spacers and multidisciplinary care.

Rectal Spacers: Revolutionizing Prostate Cancer Treatment

Practice Management in Prostate Cancer:  Key Challenges and Practical Solutions

A panel of experts discuss recent advances and key updates on the use of PSMA-targeted PET imaging in patients with prostate cancer.

PSMA-PET Imaging for Prostate Cancer: Recent Advances and Key Updates

Expert panelists review the evolving roles of PSMA-targeted PET imaging and conventional imaging in patients with prostate cancer.

Advances in PSMA-Targeted PET Imaging for Prostate Cancer 

Reactions to the emergence of novel immunotherapy agents for treatment of bladder cancer, including increased administration in community urology practices, and recommendations for sequencing newer therapies into treatment algorithms.

Immunotherapies in Treatment of Bladder Cancer

Neal Shore, MD, FACS; Bobby Liaw, MD; Vivek K. Narayan, MD, MS; and Ashley E. Ross, MD, PhD, share key insights on advances in the use of androgen receptor inhibitors (ARIs) and discuss the urologist’s role in managing patients with mCSPC and nmCRPC.

Management of Advanced Prostate Cancer in Urology: Update on Androgen Receptor Inhibitors

Experts in treating prostate cancer highlight recent clinical data and discuss practical implications for patient care.

Evolving Treatment Approaches for Advanced Prostate Cancer